Evidence map›Paper›PMID 42512035›Full record

ReviewBiomedicines2026

Recent Advances in Anticancer Activity of Gold(I) Complexes.

Nikhil Bhimsing Khandale, Jitendra Gour, Iqubal Singh, Chandan Bhogendra Jha, Avani Farasrami, Neeraj Kumar Chouhan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nikhil Bhimsing KhandaleDepartment of Pharmaceutical Chemistry, Nims Institute of Pharmacy, Nims University Rajasthan, Jaipur 303121, Rajasthan, India.ORCID 0000-0001-7654-3595
Jitendra GourDepartment of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, Telangana, India.
Iqubal SinghSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
Chandan Bhogendra JhaDepartment of Chemical Engineering, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.
Avani FarasramiFlamma USA LLC, 383 Phoenixville Pike, Malvern, PA 19355, USA.
Neeraj Kumar ChouhanDepartment of Pharmaceutical Chemistry, Nims Institute of Pharmacy, Nims University Rajasthan, Jaipur 303121, Rajasthan, India.ORCID 0000-0002-5940-8639

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical success of cisplatin has significantly spurred the exploration of new organometallic complexes in oncology. In this quest, repurposing of auranofin as an anticancer agent has diverted the research interest from platinum to gold complexes, as gold offers unique chemical features; among them, thioredoxin reductase (TrxR) inhibition is one of the most extensively studied anticancer pathways. In this study, we have compiled the major ligand modifications reported for gold(I) complexes and categorized them into various groups, which include sulfur-based ligands, nitrogen-containing heterocyclic ligands, carbon-derived ligands, and

Indexed as

anticancerdonor ligandsgold(I) complexin vitro studiesthioredoxin reductase

Identifiers

PMID42512035
PMCPMC13405613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.